Biologicals dramatic advances in the treatment of psoriasis

Current Pharmaceutical Design

Volumn 12, Issue 8, 2006, Pages 989-999

  Wilsmann Theis, Dagmar ^a   Martin, Saskia ^a   Reber, Michael ^a   Kwiek, Barlomiej ^a   Bieber, Thomas ^a   Natalija, Novak ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Alefacept; Biologicals; Efalizumab; Etanercept; Fusion protein; Human antibody; Infliximab; Recombinant human protein; Therapy of psoriasis

Indexed keywords

ABATACEPT; ALEFACEPT; ANTIHISTAMINIC AGENT; AUTOANTIBODY; BASILIXIMAB; BIMOSIAMOSE; BMS 18667; CD2 ANTIGEN; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; DACLIZUMAB; DENILEUKIN DIFTITOX; EFALIZUMAB; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; ETRETIN; GALIXIMAB; HU 1124; HYBRID PROTEIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 3; PLACEBO; RECOMBINANT PROTEIN; SIPLIZUMAB; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN PRESENTING CELL; BIOTECHNOLOGY; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE INACTIVATION; GENE TARGETING; HEADACHE; HUMAN; HYPOTENSION; INFECTION; INJECTION SITE REACTION; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; UPPER RESPIRATORY TRACT INFECTION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; CELL ADHESION; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-10; PSORIASIS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645990344     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776055930     Document Type: Review

References (72)

1. Griffiths CEM, Camp RDR, Barker JNWN. Psoriasis. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. Rook's textbook of Dermatology. Seventh Edition. Psoriasis. Blackwell publishing company, Malden, Oxford, Victoria 2004; 35.1-69.
2. Weinstein GD, Krueger JG. An overview of psoriasis. In: Weinstein GD, Gottlieb AB eds. Therapy of Moderate to Severe Psoriasis. Portland National Psoriasis Foundation, Portland, Oregon 1993; 1-22.
3. Christophers E, Kiene P. Guttate and plaque psoriasis. Dermatol Clin 1995; 13(4): 751-6.
4. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-20
5. Tremblay JF, Bissonnette RJ. Topical agents for the treatment of psoriasis, past, present and future. Cutan Med Sung 2002; 6(3 Suppl): 8-11. Epub 2002; Apr 30.
6. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152(4): 597-615.
7. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-204.
8. Friedrich M, Sterry W, Asadullah K. Novel developments in the systemic treatment of psoriasis. J Dtsche Dermatol Ges 2003; 1: 12-21.
9. Prinz JC. Latest aspects in psoriasis pathogenesis. Hautarzt 2003; 54: 209-14.
10. Ockenfels HM. Trigger factors for psoriasis. Hautarzt 2003; 54: 215-23.
11. Ghoreschi K, Rocken M. Immunpathogenesis of Psoriasis. J Dtsche Dermatol Ges 2003; 1: 524-532
12. Gottlieb AB. Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances. J Investig Dermatol Symp Proc 2004; 9(1): 79-83.
13. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003; 49: 44-50.
14. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002; 138: 657-63.
15. Mrowietz U. Psoriasis therapy with biologicals. Hautarzt 2003; 54: 224-9.
16. Friedrich M, Philipp S, Sabat R, Asadullah K, Sterry W. Use of biologicals in psoriasis. Z Rheumatol 2003; 62: 439-49.
17. Krueger GG, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003; 49: 87-97.
18. Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 2003; 148: 784-8.
19. Ellis CN, Krueger GG. Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-55.
20. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003; 25: 2487-505.
21. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719-27.
22. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47: 821-33.
23. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol 2003; 49: 98-104.
24. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002; 138: 591-600.
25. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted Tell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-13
26. Gottlieb AB, Miller B, Lowe N, Shapiro W, Hudson C, Bright R, et al. Subcutaneously Administered Efalizumab (Anti-CD11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis. J Cutan Med Surg 2003; 7(3): 198-207.
27. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290: 3073-80.
28. Cather JC, Cather JC, Abramovits W. Investigational therapies for psoriasis. J Am Acad Dermatol 2003; 49: 133-8.
29. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, et al. Mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243-52.
30. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192: 681-94.
31. Gottlieb AB, Lebwohl M, Totoritis MC, Abdulghani AA, Shuey SR, Romano P, et al. Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody. J Am Acad Dermatol 2002; 47: 692-700.
32. Mrowietz U. Treatment targeted to cell surface epitopes. Clin Exp Dermatol 2002; 27: 591-6.
33. Skov L, Kragballe K, Zachariae C, Obitz ER, Holm EA, Jemec GB, et al. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol 2003; 139: 1433-9.
34. Gottlieb AB, Lebwohl M, Shirin S, Sherr A, Gilleaudeau P, Singer G, et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol 2000; 43: 595-604.
35. Aruffo A, Hollenbaugh D. Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease. Curr Opin Immunol 2001; 13: 683-6.
36. Martin A, Gutierrez E, Muglia J, McDonald CJ, Guzzo C, Gottlieb A, et al. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389) IL-2) in patients with severe psoriasis. J Am Acad Dermatol 2001; 45: 871-81.
37. Krueger JG, Walters IB, Miyazawa M, Gilleaudeau P, Hakimi J, Light S, et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T-cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000; 43: 448-58.
38. Mrowietz U, Zhu K, Christophers E. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch Dermatol 2000; 136: 675-6.
39. Salim A, Emerson RM, Dalziel KL. Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker). Br J Dermatol 2000; 143: 1121-2.
40. Bhushan M, Bleiker TO, Ballsdon AE, Allen MH, Sopwith M, Robinson MK, et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol 2002; 146: 824-31.
41. Schon MP, Krahn T, Schon M, Rodriguez ML, Antonicek H, Schultz JE, et al. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat Med 2002; 8: 366-72.
42. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 2002; 22: 146-67.
43. Montero E, Falcon L, Morera Y, Delgado J, Amador JF, Perez R. CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease. Autoimmunity 1999; 29: 155-6.
44. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol 2003; 49: 112-7.
45. Al-Salem IH. Striking and rapid improvement of plaque psoriasis with infliximab. A report of two cases. Dermatology 2003; 207: 54-6.
46. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7.
47. Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int 2002; 22: 227-32.
48. Mahe E, Descamps V, Grossin M, Fraitag S, Crickx B. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Demtatol 2003; 149: 170-3.
49. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22
50. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-32.
51. Goffe B, Cather JC. Etanercept: An overview. J Am Acad Dermatol 2003; 49: 105-11.
52. Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MH. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 2003; 28: 604-7
53. Reimold AM. TNF-alpha as therapeutic target: new drugs, more applications. Curr Drug Targets Inflamm Allergy 2002; 1: 377-92.
54. Rose-John S, Schooltink H. CDP-870. Celltech/Pfizer. Curr Opin Investig Drugs 2003; 4: 588-92.
55. Nikas SN, Drosos AA. Onercept. Serono. Curr Opin Investig Drugs 2003; 4: 1369-76.
56. Trinchard-Lugan I, Ho-Nguyen Q, Bilham WM, Buraglio M, Ythier A, Munafo A. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers. Eur Cytokine Netw 2001; 12: 391-8.
57. Scheinfeld N. Adalimumab (HUMIRA): a review. J Drugs Dermatol 2003; 2: 375-7.
58. Kennewell P. Technology evaluation: ISIS-104838, OraSense. Curr Opin Mol Ther 2003; 5: 76-80.
59. Mee JB, Alam Y, Groves RW. Human keratinocytes constitutively produce but do not process interleukin-18. Br J Dermatol 2000; 143: 330-6.
60. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003; 112: 1571-80.
61. Homey B. Interleukin-4: a new option in the therapy of systemic psoriasis? Hautarzt 2003; 54: 1019-20.
62. Ghoreschi K, Mrowietz U, Rocken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med 2003; 81: 471-80.
63. Asadullah K, Docke WD, Ebeling M, Friedrich M, Belbe G, Audring H, et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 1999; 135: 187-92.
64. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998; 101: 783-94.
65. Friedrich M, Docke WD, Klein A, Philipp S, Volk HD, Sterry W, et al. Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis. J Invest Dermatol 2002; 118: 672-7.
66. Sitaraman SV, Gewirtz AT. Oprelvekin. Genetics Institute. Curr Opin Investig Drugs 2001; 2: 1395-400.
67. Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, Bliss JL, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999; 104: 1527-37.
68. Lebwohl M. Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol 2003; 49: 118-24.
69. Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151(Suppl 69): 3-17.
70. Christopherson KW 2nd, Hromas RA. Endothelial chemokines in autoimmune disease. Curr Pharm Design 2004; 10(2): 145-54.
71. Kisliuk RL. Deaza analogs of folic acid as antitumor agents. Curr Pharm Design 2003; 9(31): 2615-25.
72. Milligan G, Feng GJ, Ward RJ, Sartania N, Ramsay D, McLean AJ, et al. G protein-coupled receptor fusion proteins in drug discovery. Curr Pharm Design 2004; 10(17): 1989-2001.